Undisclosed HFrEF Program
Heart Failure with Reduced Ejection Fraction (HFrEF)
Key Facts
About NanoPhoria Bioscience
NanoPhoria Bioscience is an Italian preclinical biotech focused on revolutionizing cardiovascular drug delivery via its proprietary inhaled Nano-in-Micro platform. The company is targeting Heart Failure with Reduced Ejection Fraction (HFrEF), a condition with significant mortality and economic burden, where current systemic therapies leave substantial residual risk. Having secured Series A funding with participation from the European Innovation Council Fund, NanoPhoria is advancing its platform technology and pipeline programs toward clinical development. The company represents a novel approach aiming to improve efficacy and patient compliance through localized, non-invasive administration of therapeutics.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| ALLAY-HFrEF | Alleviant Medical | Pivotal Trial |
| Neucardin® | Zensun Sci & Tech | Phase 2/3 |
| Cardiac Contractility Modulation (CCM) Implant | Berlin Heals | Pre-clinical / Early Clinical |
| SRD001 (inferred) | Sardocor | Phase 1 |
| AC01 | AnaCardio | Phase 2 |
| Firibastat | Quantum Genomics | Phase II |
| Omecamtiv Mecarbil | Cytokinetics | Phase 3 |